Fulgent Genetics, INC

Fulgent Genetics announced its second quarter 2026 financial results, reporting $85.4 million in revenue and a GAAP net loss of $29.5 million, while revising annual revenue guidance.

Fulgent Genetics announced interim Phase 2 results for FID-007 in head and neck cancer, showing a 60% objective response rate and significantly improved progression-free survival compared to standard care.

Fulgent Genetics stockholders approved the 2026 Equity Incentive Plan at the annual meeting, replacing the prior plan and authorizing new share issuances.

Fulgent Genetics, through its subsidiary Inform Diagnostics, has completed the acquisition of Bako Diagnostics and StrataDx for a combined cash purchase price of approximately $56.9 million.

Fulgent Genetics announced its Q4 and full-year 2025 financial results, reporting revenue growth in its laboratory services and progress in its therapeutic pipeline, while providing 2026 guidance.

Fulgent Genetics expands its laboratory services with the acquisition of Bako Diagnostics and StrataDx for a combined $55.5 million in cash.

Fulgent Genetics reported a 4% revenue increase for Q2 2026, driven by its anatomic pathology segment, but faced a significant gross margin decline due to system implementation issues and increased costs.

Fulgent Genetics reported a 17% increase in third-quarter revenue driven by strong growth in precision diagnostics and BioPharma services, while significantly narrowing its net loss.

Fulgent Genetics announced a 15% revenue increase for the second quarter and first half of 2025, driven by growth in precision diagnostics, anatomic pathology, and BioPharma services, despite reporting a significantly higher net loss due to an impairment charge and increased operating expenses.

Fulgent Genetics' Q1 2025 revenue increased by 14% year-over-year, driven by growth in precision diagnostics and anatomic pathology, while the company continues to invest in its therapeutic development business.

Fulgent Genetics experienced a revenue decrease in Q3 2024, primarily due to reduced COVID-19 testing revenue, while precision diagnostics showed growth.

Fulgent Genetics reported a net loss for the second quarter of 2024, while facing ongoing legal investigations and making strategic shifts in its business segments.

Fulgent Genetics reported a 14% revenue increase to $322.7 million in 2025, alongside a 42% rise in net loss to $60.5 million, driven by strategic acquisitions and R&D investments.

Fulgent Genetics' 10-K filing reveals a year of strategic shifts, balancing diagnostic services with a growing emphasis on therapeutic development amidst evolving regulatory landscapes.

Fulgent Genetics' 2023 10-K filing highlights a strategic shift towards precision medicine and oncology, amidst a significant decline in COVID-19 testing revenue.

Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc., reported a transaction in 2,747 shares of common stock on July 26, 2026.

Jian Xie, President and COO of Fulgent Genetics, Inc., reported a transaction in 4,361 shares of common stock on July 26, 2026.

Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc., reported a transaction in 1,645 shares of common stock on July 26, 2026.

Fulgent Genetics President and COO Xie Jian sold 2,146 shares of common stock to cover tax obligations related to RSU vesting.

CFO Paul Kim disposed of 2,087 shares of Fulgent Genetics common stock to satisfy tax obligations related to RSU vesting.

Chief Scientific Officer Hanlin Gao sold 1,688 shares of Fulgent Genetics to cover tax obligations related to RSU vesting.

Fulgent Genetics has filed a definitive proxy statement with the SEC, signaling preparations for an upcoming shareholder meeting.

Fulgent Genetics sets date and agenda for its 2025 Annual Meeting of Stockholders, including director elections and executive compensation approval.

Fulgent Genetics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Fulgent Genetics announces its 2024 Annual Meeting of Stockholders to be held on May 16, 2024, focusing on director elections, auditor ratification, and executive compensation approval.

CEO Ming Hsieh reports a change in beneficial ownership of Fulgent Genetics common stock following equity award vesting.

Fulgent Genetics CEO Ming Hsieh and his Trust updated their beneficial ownership, revealing equity award vestings, tax-related sales, and significant share pledges.

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, reporting a 3.0% beneficial ownership in Fulgent Genetics, Inc. as of December 31, 2025.

Millennium Management LLC and affiliated entities, including Israel A. Englander, have disclosed a passive beneficial ownership of 5.6% in Fulgent Genetics, Inc. common stock.

Millennium Management LLC and its affiliates have filed an Amendment No. 2 to their Schedule 13G, disclosing a 4.7% beneficial ownership stake in Fulgent Genetics, Inc. as of June 30, 2025.

Barclays PLC has filed an Amendment No. 2 to Schedule 13G, reporting a 7.57% beneficial ownership stake in Fulgent Genetics Inc. as of March 31, 2025.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has filed an amended Schedule 13G, disclosing a 6.5% beneficial ownership stake in Fulgent Genetics, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.9% beneficial ownership in Fulgent Genetics, Inc. as a passive institutional investor.